Skandinaviska Enskilda Banken (SEB)
CBMG

Skandinaviska Enskilda Banken (SEB)’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-46,355
Closed -$852K – 1235
2020
Q4 		$852K Hold
46,355
– – 0.01% 842
2020
Q3 		$850K Buy
+46,355
New +$779K 0.01% 760

Skandinaviska Enskilda Banken (SEB)'s CBMG Position: Q1 2021 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 46,355 shares — an estimated $852K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in CBMG in Q3 2020 and held it in 2 quarters. The position peaked at $852K in Q4 2020. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 46,355 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $852K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Cellular Biomedicine Group, Inc. in Q3 2020 and held it in 2 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Cellular Biomedicine Group, Inc. position peaked at $852K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2021, filed 14 May 2021.